Inovio spinout plans pivotal study for cancer vaccine as it touts alternative take on PhIb/IIa liver cancer data
22 Aug 2023
VaccineClinical Study
Inovio spinout Geneos Therapeutics said Tuesday that it has three new partial responses and one case of stable disease from a mid-stage liver cancer trial testing its personalized cancer vaccine candidate in combination with Merck’s Keytruda. However, the biotech is claiming these responses as “complete molecular responses.”
Geneos reported the four “complete molecular responses” Tuesday morning, touting an analysis of the patient’s circulating tumor DNA, or ctDNA. That metric offers a different picture from RECIST1.1, which Geneos CEO Niranjan Sardesai acknowledged is the gold standard for determining objective responses, or changes in tumor size.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.